Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
(±)-Anatoxin A fumarate (HB2023)
Description:Potent nicotinic agonist. Apoptosis inducer.
Purity:>99%
Anisomycin (HB2239)
Description:Protein synthesis inhibitor. Potent JNK / p38 MAPK activator.
Purity:>98%
- Description:
Identifies early apoptotic, necrotic and viable cells
Aphidicolin (HB3690)
Description:DNA replication inhibitor. Useful for cell synchronization
Purity:>98%
Aranorosin (HB3768)
Description:Antibiotic with antibacterial, anticancer and antifungal activity
Purity:>95%
(S)-(+)-Ascochin (HB3702)
Description:Antibiotic with antifungal and phytotoxic activity
Purity:>98%